HMGN2P7: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

Target Name: HMGN2P7

NCBI ID: G644498

HMGN2P7

Other Name(s): High mobility group nucleosomal binding domain 2 pseudogene 7 | high mobility group nucleosomal binding domain 2 pseudogene 7 | HMGN2L7

HMGN2P7: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Diseases

High mobility group nucleosomal binding domain (HMGN2) is a gene that encodes a protein involved in the maintenance of chromosomal stability. The HMGN2 gene has four splice variants, but only one functional variant, HMGN2P7, is expressed in human tissues and has been implicated in the development and progression of various diseases. HMGN2P7 has been identified as a potential drug target and a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Expression and Localization of HMGN2P7

HMGN2P7 is a 21-kDa protein that localizes to the nucleosome. The nucleosome is the basic unit of chromatin that consists of DNA, RNA, and proteins that work together to ensure the proper organization and accessibility of genetic information. HMGN2P7 interacts with the histone protein H2A and the linker protein S100 to form the nucleosome.

HMGN2P7 has been shown to play a role in regulating chromatin dynamics, including the levels of histone modifications, such as acetylation and methylation, that affect gene expression. It has also been shown to interact with other proteins involved in chromatin regulation, including the transcription factor TFAP2 and the protein p16INK4a.

HMGN2P7 is also involved in the regulation of cellular processes that are critical for the survival of cells, such as cell division, apoptosis, and autophagy. These processes are regulated by a complex interplay of genetic and epigenetic factors, including the action of histone modifications and chromatin variability.

Disease association and potential therapeutic targets

HMGN2P7 has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, HMGN2P7 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. It has also been shown to interact with the transcription factor EGFR and to play a role in the development of resistance to chemotherapy in cancer cells.

In neurodegenerative diseases, HMGN2P7 has been implicated in the regulation of neurotransmitter synthesis and storage, as well as the maintenance of cellular stability. It has also been shown to interact with the protein autonomous ribosome and transfer RNA, sarcosome-associated protein 2 ( SAPS2), and to play a role in the development of neurodegeneration in dopamine-dependent neurons.

In autoimmune disorders, HMGN2P7 has been implicated in the regulation of immune cell function and the development of autoimmune diseases. It has also been shown to interact with the transcription factor NF-kappa-B and to play a role in the regulation of inflammation and autoimmune diseases.

Conclusion

HMGN2P7 is a gene that has been shown to play a role in the regulation of various cellular processes that are critical for the survival of cells. It has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders . As a potential drug target and biomarker, HMGN2P7 is a promising target for the development of new therapies for these diseases.

Protein Name: High Mobility Group Nucleosomal Binding Domain 2 Pseudogene 7

The "HMGN2P7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMGN2P7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets